Multi-Organ MRI Enables Smarter, Mechanism-Driven CKLM Trials

• Label expansion is accelerating across CV, CKD, HFpEF and MASH, and CKLM trials would benefit from measuring cross-organ response, not just weight or eGFR
• Ectopic fat imaging (renal, cardiac, pancreatic, hepatic) quantifies cardiometabolic risk and treatment response at the tissue level
• Multi-organ inflammation, fibrosis and perfusion biomarkers capture therapeutic benefit beyond fat loss, enabling earlier readouts and stronger regulatory narratives

Speakers:

Caitlin Langford

Senior Director, Product, Pharma Solutions

Perspectum